Longleaf Partners Fund, managed by Southeastern Asset Management, saw a -0.33% return in Q3 2025, compared to S&P 500’s 8.12% and Russell 1000 Value’s 5.33%. Despite flat performance, the firm emphasizes investments in real assets and brands to drive growth. For top picks, check its top five holdings.

Bio-Rad Laboratories, Inc. (NYSE:BIO) featured in Longleaf Partners Fund’s Q3 2025 letter, with a one-month return of 24.80%. On Oct 23, the stock closed at $338.67 per share, with a market cap of $8.893 billion. The company is a life science research and clinical diagnostic products provider.

Longleaf Partners Fund highlights Bio-Rad Laboratories, Inc. (NYSE:BIO) as a positive contributor due to steady earnings in a tough market. The company is poised for earnings growth in 2026, with a strong investment in Sartorius. With a net cash balance sheet, Bio-Rad continues to repurchase shares.

Bio-Rad Laboratories, Inc. (NYSE:BIO) is not among the 30 Most Popular Stocks Among Hedge Funds. While 42 hedge fund portfolios held BIO in Q2, there’s potential for AI stocks with greater upside and less downside risk. Consider exploring undervalued AI stocks poised to benefit from current trends.

Read more at Yahoo Finance: Bio-Rad (BIO) Surged as the Earnings Exceeded Expectations